Autophagy promotes
cancer cell survival in response to p53 activation by the
anticancer agent Nutlin-3a (Nutlin). We reported previously that Nutlin kills MDM2-amplified
cancer cells and that this killing is associated with an inhibition of
glucose metabolism, reduced α-ketoglutarate (α-KG) levels, and reduced autophagy. In the current report, using SJSA1, U2OS, A549, and MHM cells, we found that Nutlin alters
histone methylation in an MDM2 proto-oncogene-dependent manner and that this, in turn, regulates autophagy-related gene (ATG) expression and cell death. In MDM2-amplified cells, Nutlin increased
histone (H) 3
lysine (K) 9 and K36 trimethylation (me3) coincident with reduced autophagy and increased apoptosis. Blocking
histone methylation restored autophagy and rescued these cells from Nutlin-induced killing. In MDM2-nonamplified cells, H3K9me3 and H3K36me3 levels were either reduced or not changed by the Nutlin treatment, and this coincided with increased autophagy and cell survival. Blocking
histone demethylation reduced autophagy and sensitized these cells to Nutlin-induced killing. Further experiments suggested that MDM2 amplification increases
histone methylation in Nutlin-treated cells by causing depletion of the
histone demethylase Jumonji domain-containing
protein 2B (JMJD2B). Finally, JMJD2B knockdown or inhibition increased H3K9/K36me3 levels, decreased ATG gene expression and autophagy, and sensitized MDM2-nonamplified cells to apoptosis. Together, these results support a model in which MDM2- and JMJD2B-regulated
histone methylation levels modulate ATG gene expression, autophagy, and cell fate in response to the MDM2 antagonist
Nutlin-3a.